Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immuneering (IMRX – Research Report) and Palatin ...

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with ...

Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.

Immuneering Co. (NASDAQ:IMRX – Get Free Report) has received a consensus recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat reports.One research ...

(RTTNews) - Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with Regeneron Pharmaceuticals. The supply agreement supports ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Overview: Immuneering Corporation is a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients, with a market cap of $65.83 million. Operations ...